



ESC Cardiovascular Round Table

CRT Workshop - 19 & 20 February 2020

“Chronic Coronary Syndrome”

Biographies

- [Dr William Wijns](#)
- [Dr Valentin Fuster](#)
- [Prof. Stephan Achenbach](#)
- [Prof. Jeroen Bax](#)
- [Dr Victoria Delgado](#)
- [Prof. David Newby](#)
- [Dr Friedrich Fuchs](#)
- [Prof. Javier Escaned](#)
- [Assoc. Prof. Yolande Appelman](#)
- [Prof. Filippo Crea](#)
- [Prof. Li-Ming Gan](#)
- [Prof. Emanuele Barbato](#)
- [Prof. Martine Gilard](#)
- [Prof. Sigrun Halvorsen](#)
- [Prof. John William McEvoy](#)
- [Dr Martin van Eickels](#)
- [Dr Nick West](#)



[William Wijns](#)

National University of Ireland Galway

Dr W. Wijns is Professor in Interventional Cardiology at the University of Ireland Galway since 2016 (Science Foundation Ireland Research Chair). Current research efforts are targeting the development and validation of innovative techniques in interventional medicine and on the development and use of biosensors, both wearable and implantable, for monitoring and modulation of event-triggering mechanisms in high-risk patients with coronary artery disease, hypertension and diabetes. Dr W. Wijns has a strong interest in adult learning, knowledge transfer techniques and education science via chairmanship of PCR Courses and other educational activities (publishing, web-based learning, seminars and workshops).



[Valentin Fuster](#)

Mount Sinai, New York, USA

Dr Valentín Fuster combines roles as General Director of the Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) in Madrid and Director of the Cardiovascular Institute and Physician-in-Chief at the Mount Sinai Medical Center, New York. He is also Editor in Chief of the Journal of the American College of Cardiology (JACC), the main source of clinical news and analysis in cardiovascular medicine, published by the American College of Cardiology.

The innumerable positions Dr. Fuster has held during his career include President of the American Heart Association, President of the World Heart Federation, member of the Institute of Medicine of the US National Academy of Sciences (where he chairs the committee for the prevention of the global epidemic in heart disease), member of the US National Heart, Lung and Blood Institute Advisory Council, and President of the American College of Cardiology Training Program.

After qualifying in medicine at the University of Barcelona, Valentín Fuster continued his studies in the USA. He was professor of Medicine and Cardiovascular Diseases at the Mayo Medical School, Minnesota and at the Medical School of Mount Sinai Hospital, New York, and from 1991 to 1994 was full professor of Medicine at Harvard Medical School in Boston. In 1994 he was named director of the Cardiovascular Institute at Mount Sinai, a post he has combined since 2012 with that of Physician-in-Chief.

Dr. Fuster has been named Doctor Honoris Causa by thirty-four universities and has received three of the most important awards from the US National Institutes of Health. He is an author on more than 1000 scientific articles in international medical journals, and has published two leading books on clinical cardiology and research: *The Heart and Atherothrombosis* and *Coronary Artery Disease*.

He is the most highly cited Spanish research scientist, according to the Cybermetrics Lab ranking, which is based on an analysis of Google Scholar. At the time of writing his work has been cited 238,436 times in the scientific literature. He also has a higher h index than any other Spanish researcher, indicating that he tops rankings for both the quantity and the quality of research. His h index is currently 187, indicating that he 187 of his publications have been cited at least 187 times in other publications.

His contributions to cardiovascular medicine have had an enormous impact on the treatment of patients with heart disease. His research into the origin of cardiovascular events, which has contributed to improved treatment of heart attack patients, was recognized in 1996 by the award of the Prince of Asturias Award for Technical and Scientific Research.

In 2012, Dr. Fuster was named by the American College of Cardiology as one of the Living Legends in Cardiovascular Medicine, and was awarded the Research Achievement Award, the highest award given by the American Heart Association.



Dr. Fuster was also recently awarded the Ron Haddock International Impact Award by the American Heart Association and the American Stroke Association in recognition of his global leadership. Further recognition in Spain came in the form of the Severo Ochoa Prize for Biomedical Research and the Mapfre Foundation Lifetime Achievement Award in recognition of his work on the prevention and treatment of cardiovascular disease. According to the evaluation committee, Dr. Fuster's career stands as a model of the kind of research and innovation in which Spain needs to excel in order to compete in the global economy.

Among his many achievements, Dr. Fuster is the only cardiologist to have received the highest research awards from the four leading international cardiology organizations: the American Heart Association, the American College of Cardiology, the European Society of Cardiology, and the Interamerican Society of Cardiology. In 2019, the Spanish Ministry of Science, Innovation and Universities awarded Dr Fuster the National Research Prize, and he was named "Physician of the Year" in the ABC Salud awards for his contribution to cardiovascular medicine and his recent research into the links between heart and brain health.

In addition to his dedication to research, Dr. Fuster is strongly committed to his responsibility to communicate to the public. In recent years, this commitment has produced six books aimed at a general audience, which have been very positively received. This vocation and the clear need to promote healthy lifestyle habits led Dr. Fuster to set up the Science, Health and Education Foundation (SHE), with the goal of improving public health, especially among young people.



[Stephan Achenbach](#)

University of Erlangen, Germany

Prof. Dr. med. Stephan Achenbach is the Chairman of the Department of Cardiology and Professor of Medicine at the University of Erlangen, Germany. The main clinical interests of Stephan Achenbach are Interventional Cardiology, General Cardiology as well as Cardiac Imaging. His research is focused on cardiac intervention and cardiac imaging, mainly computed tomography, with an emphasis on imaging of coronary atherosclerosis and imaging to support coronary and structural interventional procedures. Stephan Achenbach was the Founding President of the Society of Cardiovascular Computed Tomography. He is President Elect and Board Member of the European Society of Cardiology (ESC) and was Chairperson of the ESC Congress Programme Committee 2016-2018. As such, he was in charge of the ESC Congress 2017 in Barcelona and 2018 in Munich with approximately 30 000 attendees.

Stephan Achenbach has received several awards, including the Jan Brod Award for Clinical Research of the Medical School of Hannover, Germany (1999), the Thomas C. Cesario Distinguished Visiting Professorship Award, University of California Irvine School of Medicine (2007), the Simon Dack Award, American College of Cardiology (2009), the Gold Medal of the Society of Cardiovascular Computed Tomography (2015) and the Sir Godfrey Hounsfield Award of the British Institute of Radiology (2016). He was selected by AuntMinnie.com as the “Most Influential Radiology Researcher” in 2017, and he has repeatedly received the Best Teaching Award, Clinical Medicine, University of Erlangen-Nürnberg (2013, 2014, 2015, 2016, 2017, 2018, 2019).



[Jeroen Bax](#)

Leiden University Medical Centre, Netherlands

ESC Immediate Past-President (2018 – 2020), Professor Jeroen Bax, FESC, is Director of non-invasive imaging and Director of the echo-lab at the Leiden University Medical Center. His main interests include clinical cardiology, heart failure, cardiac resynchronization therapy and the application of all different imaging modalities to these clinical fields. Professor Bax has authored numerous papers and holds several positions in national and international scientific organizations, as well as serving on the editorial boards of many different journals.



[Victoria Delgado](#)

Leiden University Medical Centre, Netherlands

Dr. Victoria Delgado got her specialization in cardiology at Hospital Clinic (Barcelona) in 2005 and her PhD in cardiac imaging at the Leiden University in 2010. She has been task force member of ESC guidelines, councillor and chair of scientific documents of the EACVI and currently is member of the ESC Practice Guidelines Committee and serves as associate editor of Circulation and the Journal of the American Society of Cardiology.

David Newby

Wellcome Trust Clinical Research Facility and Edinburgh Imaging, Edinburgh, Scotland

Professor David Newby graduated from the University of Southampton with a Bachelor of Science and Bachelor of Medicine degree in 1991. He has worked in Edinburgh for over 25 years and obtained Doctorates in Medicine, Philosophy and Science. Professor Newby is British Heart Foundation Duke of Edinburgh Chair of Cardiology at the University of Edinburgh, Director of the Wellcome Trust Clinical Research Facility, Director of Edinburgh Imaging facilities, and a Consultant Interventional Cardiologist at Royal Infirmary of Edinburgh.

Professor Newby has major interests in experimental medicine, advanced imaging and clinical trials of cardiovascular disease including coronary heart disease, aortic stenosis and heart failure. He currently holds a British Heart Foundation Programme Grant and a Wellcome Trust Senior Investigator Award to explore advanced imaging in coronary heart disease. He also has a major interest in the atherothrombotic effects of air pollution, and the interaction between cardiac and respiratory diseases. He has been involved in several multicentre trials and has played a major role in the conduct of the SALTIRE (Scottish Aortic stenosis Lipid lowering Trial, Impact on REgression) and 3CPO (Health Technology Assessment trial of non-invasive ventilation for acute cardiogenic pulmonary oedema) trials. He is Chief Investigator for the SCOT-HEART trial funded by the Chief Scientist Office; a national multicentre randomised controlled trial of computed tomography coronary angiography. He is Chief Investigator of the Wellcome Trust-funded multicentre trial: Prediction of Recurrent Events with ¹⁸F-Fluoride to Identify Ruptured and High-risk Coronary Artery Plaques in Patients with Myocardial Infarction (PRE¹⁸FFIR) trial and the British Heart Foundation funded DUAL antiplatelet therapy in Acute Coronary Syndromes in Scotland (DUAL-ACS²) and SCOT-HEART 2 trials.

For his research, Professor Newby was awarded the British Association of Pharmaceutical Physicians' Prize, the Croom Lectureship (Royal College of Physicians, Edinburgh), the BUPA research award for the best emerging clinical researcher in the UK, the John French Award (British Atherosclerosis Society), the Goodall-Strickland Medal (British Cardiovascular Society), the Parmley Prize (American College of Cardiology) and British Medical Journal Research Awards 2014. In 2017, his team won the British Medical Journal Imaging Team of the Year Award. In 2018, he was awarded the MacKenzie Medal by the British Cardiovascular Society and Silver Medal by the European Society of Cardiology. He has written several successful educational books that have received major national awards (British Medical Association Book Awards, Highly Commended: *Coronary Heart Disease: Your Questions Answered*; Society of Authors, First Prize (Richard Asher Prize): *Cardiology: An Illustrated Coloured Text*). For his research and training, he and the British Heart Foundation Centre for Cardiovascular Science were awarded the Queen's Anniversary Prize 2014-2016.

Professor Newby is Deputy Editor of *Heart* and was Chair for the development of the Scottish Intercollegiate Guideline Network (SIGN) guidelines for the management of acute coronary syndromes.



Friedrich Fuchs

Siemens Healthineers AG, Germany

Friedrich Fuchs is a board-certified cardiologist and Fellow of the ESC, who joined Siemens Healthcare over a decade ago. After various positions in the business line MRI, the Medical Office and Healthineers company strategy, FF is now serving as Medical Officer within the Cardiology business line of Siemens Healthineers.



[Javier Escaned](#)

Hospital Clínico San Carlos, Madrid, Spain

Prof. Javier Escaned is Head of the Interventional Cardiology Section at Hospital Clinico San Carlos, Universidad Complutense de Madrid (Madrid, Spain). He obtained his specialist certification as a cardiologist the United Kingdom before moving to the Thoraxcenter / Rotterdam (The Netherlands), where he obtained his PhD degree in 1994. He is author of over 390 indexed scientific articles (h-index 60).

A skilled interventionalist with 30 years of experience, he regularly shares practical knowledge as live case operator in case transmissions to major global meetings. One of his main interest is complex PCI, an area in which he has published multiple works on subsets like multivessel disease (principal investigator of SYNTAX II study), left main, chronic total occlusion, calcific stenoses, secondary revascularization, acute coronary syndromes, and procedural guidance with physiology and imaging techniques (OCT and IVUS).

A pioneer author on IVUS and an early adopter of OCT, his track record in coronary physiology includes being investigator in the pivotal DEFER study on FFR (1998), collaborator in the development, validation and clinical implementation of resting indices of stenosis severity (iFR) (since 2010) and developer of new methods for the assessment of microvascular and non-obstructive coronary disease. Recent trials as principal investigator on intracoronary diagnostics include ADVISE, ADVISE II, DEFINE FLAIR, and ABSORB II Physiology, and ReVEAL. He has served as Task Force member for several ESC Clinical Practice Guidelines (most recent, 2019 Chronic Coronary Syndromes). His latest editorial contributions in the field of imaging and physiology are the textbooks “Coronary Stenosis. Imaging, Structure and Physiology”, (co-edited with Patrick W Serruys) and “Physiological Assessment of Coronary Stenoses and the Microcirculation) (co-edited with Justin Davies).

As an educationalist he has trained and worked continuously with PCR since 2009, serving as international faculty at EuroPCR, Gulf PCR and Asia PCR. Besides, he has served as co-director of multiple courses on interventional cardiology held in European, Asian and Australian locations.

Recent / current board positions in scientific societies include EuroPCR, EAPCI, EuroCTO and the ESC Working Group of Coronary Pathophysiology and Microcirculation. Some of his additional interests are philosophy, education and music.



[Yolande Appelman](#)

VU University Medical Center, Amsterdam, The Netherlands

Education/Academic background: Master Medicine University of Amsterdam (UvA) (1989), Physician at UvA (1991), PhD UvA (1996), Cardiologist UvA (2001), Interventional cardiologist St. Antonius Nieuwegein (2004), Interventional Cardiologist with research focus on ACS and non-obstructive coronary artery disease and gender differences (2006 onwards).

Current job title: Associate professor

Affiliation: Interventional cardiologist Amsterdam UMC, location VUmc 2005 and onwards

Initiator and first chair of: Working group on Gender of the Dutch Society of Cardiology (NVVC) (2008-2013) and Thinktank of Gender&Health VUmc (2016-). In the Netherlands I am one of the ambassadors on gender and CVD and well known in the national public media. Obtained various research grants on gender and CVD and supervising PhD students. Participating as co-applicant in several trials on gender and CVD. Member of the steering committee of European Association of PCI in Women Committee (EAPCI-Women) and chair of Education and Training; Participated in the Gender&Health Knowledge Agenda of ZonMw;

My ambition is to move this field forward and to enrich the knowledge gap in non-obstructive CAD in women. My track record shows my ambition, and my perseverance is, among other things necessary for success of the project. I will also use my enthusiasm and organizing skills to accomplish a good team effort, by working with different professionals and also the participating representatives of the patient organization 'de Harteraad'.

Professional track record

1. Relevant professional positions and activities: (e.g. management or advisory tasks), clinical tasks, teaching etc.

- Interventional cardiologist with focus on functional invasive coronary measurements (60%); Chair Think-tank on Women&Health AUMC, location VUmc; Co-chair Workinggroup on Women and NOCAD Netherlands Heart Institute (NHI); Teaching trainee cardiologists and fellow interventional cardiologists in the cathlab on daily basis; Member advisory board of biotech company (Regencor); Outpatient clinic, supervising Coronary Care Unit, daily patient tasks including heartteam etc. (15%); Teaching medical students and trainees cardiology on cardiovascular disease in women (2%); Research (10%).

2. Other Experience and Professional Memberships (e.g. membership of a scientific society, membership of boards, participation in user committees, etc.)

- Member of: The EURObservational Research Programme on ACS (ESC); Steering Committee EAPCI Women and chair of Training & Education on Women in Interventional Cardiology; Databases & Registries Committee ESC; WOMEN Inc Alliance Women&Health Netherlands later Dutch Society of Gender&Health; Steering Committee of the Working Group of ACS, part of the Netherlands Society of Cardiology (NVVC); Initiator-Chair and later member of Working group on Gender NVVC; The European Society of Cardiology (ESC); Working group of Interventional Cardiology (WIC), NVVC.

- Membership of boards: The Editorial Board EuroIntervention; Lancet Committee on Gender & CV disease; Chair of the Think Tank Gender and Health of Amsterdam UMC, location VUmc; The Editorial Board Netherlands Heart Journal and European Journal Interventional Cardiology.



Societal track record

1. Relevant societal positions and activities: Fundraising, organizer of meetings and other

- Yearly cycle event from Netherlands to ESC for amongst other things fundraising Women and CVD; Participator in cycle event from Trondheim to Oslo (Den store Styrkeproven 543km) for fundraising PLN cardiomyopathy; 2018 Symposium on Women in interventional cardiology: with prof dr Roxana Mehran, Mount Sinai NY; Yearly event Dress Red Day on Sept 29th AUMC, for health care professionals and broad public; 2018 Crowdfunding DHF on microvascular disease in women (60K); 2017 Symposium on how to implement sex and gender in research, VUmc. 2017 The National Women and Health Day at VUmc in collaboration with Zus&Zorg and WomenInc; Several meetings on women and cardiovascular disease for general practitioners and broad public and during yearly National Health Day, Jaarbeurs Utrecht; 2013 Women and Career in Cardiology, ESC meeting Amsterdam

- Volunteer work: Board member of foundation: Heroes of Care (Helden van de Zorg) for the support of people who work in care and need extra appreciation for their work www.heldenvandezorg.nl

2. Best 5 selected non-scientific outputs, e.g. policy documents, guidelines, newspaper articles, etc.

- The Female Heart: 'Desired and less underappreciated' a Guideline in CVRM in Women (2nd edition edition Y. Appelman&J. Roeters van Lennip ISBN 978-90-368-1809-4 BSL 2017; Percutaneous treatment of cardiac diseases in women. Chapter I by Appelman Y and ten Haaf M. ISBN 978-3-319-39609-5. DOI: 10.1007/978-3-319-39611-8. 2016; Gender and Health Knowledge Agenda ZonMw DOI 10.13140/RG.2.1.3459.0880; Nominated by magazine "Opzij" as one of the most important influential women on Women&Health of 2018 in The Netherlands; December 2018 ; Appearance in the public television program 'Pauw' 2017 on CVD in women. <https://www.uitzendinggemist.net/aflevering/405581/Pauw.html#>

Valorisation track record

- Relevant positions and activities for valorisation of research: (e.g. collaboration with industry, IP rights claimed, contribution to start-up companies, seed money/valorisation grants, etc.)

- Founder of a new company DutchCardio later renamed to ICC on image guided plaque ablation USP 945593



Filippo Crea

Catholic University of the Sacred Heart, Rome, Italy

Filippo Crea was born in Cosenza, Italy on 19 September 1953. He graduated from Pisa Medical School with full honours in 1977 and passed the Postgraduate Boards in both Pulmonary and Cardiovascular Diseases, again with full honours, at Pisa Medical School in 1980 and 1983 respectively. During the whole of 1984 he was Research Fellow at the Division of Cardiology of the University of Florida, directed by Professor Richard C. Conti. From 1985 to 1991 he was Honorary Clinical Assistant and then Senior Lecturer and Honorary Consultant at the Cardiovascular Research Unit of the Hammersmith Hospital in London, directed by Professor Attilio Maseri. He returned to Italy upon his appointment as Chief of the Catheterization Laboratory at the Institute of Cardiology of the Catholic University in Rome. In 2000 he became Associate Professor of Cardiology and Chief of the Intensive and Sub-Intensive Care Unit. In 2001 he became Professor of Cardiology, Director of the Institute of Cardiology and Director of the Postgraduate School in Cardiology at the Catholic University in Rome. Since October 2008 he is Director of the Department of Cardiovascular Sciences.

He is a Fellow of the American College of Cardiology and of the European Society of Cardiology, Past Chairman of the Working Group of Microcirculation and Past Member of the Congress Programme Committee of the European Society of Cardiology.

He is International Associate Editor of “the European Journal of Cardiology”, member of the Editorial Board of “Circulation”, “Clinical Cardiology” and “Revista Española de Cardiología”, past Associate Editor of “Heart” and past Deputy Editor of the Italian Heart Journal.

In 1992 he received from Professor Rita Levi Montalcini the Newburg Prize for his scientific contribution to the cardiovascular research.

In 2013 he received the Arrigo Recordati International Prize for lifetime achievement in researching the pivotal role of microcirculation in systemic and organ diseases. In 2015 delivered the 7th annual Robert L. Krakoff International Lecture in Cardiovascular Medicine at the Brigham and Women’s Hospital, Harvard University Medical School, Boston USA.

His main fields of interest are coronary microcirculation, acute coronary syndromes and stem cells.

He is the author of more than 890 publications in peer reviewed journals with an H-Index of 73.



Li-Ming Gan

AstraZeneca, Göteborg, Sweden

Li-Ming Gan is Vice president and Head of early clinical development at AstraZeneca and responsible for phase 1 up to ph2b clinical trials within cardiovascular, renal and metabolism disease areas. Been with AZ for 18 years and has held positions as preclinical portfolio and science lead, translational science director, senior medical science director, as well as Chief scientist prior to his current position. In parallel with his position at AZ, Li-Ming Gan also holds a position as professor/chief physician at the department of cardiology, Sahlgrenska University Hospital and Sahlgrenska Academy in Göteborg, Sweden. Academically, Li-Ming is a translational physician scientist focusing on cardiovascular research and functional imaging techniques from preclinical animal models to humans to improve tools to diagnose and risk-stratify high-risk CV patients with particular interest in coronary microvascular diseases.



Emanuele Barbato

Department of Advanced Biomedical Sciences, University Federico II, Naples, Italy

Diplomas

Professor of Cardiology - Faculty of Medicine of the Federico II University of Naples, Italy

In 1997, he graduated in Medicine, and in 2001 he obtained the board certification in Cardiology at the University of Naples Federico II. During the medical school he attended in the frame of a short-stay research fellowship, sponsored by the University of Naples Federico II, the Cardiology Molecular Lab of prof. Walter J. Koch at the Duke University in North Carolina. From Jan 2001 to Dec 2002, he was Clinical Research Fellow at the Cardiovascular Research Center of Aalst (Belgium). In May 2006, he completed the PhD in Cardiovascular Pathophysiology at the University Tor Vergata in Rome. In 2007, Prof. Barbato was appointed as Associate Director of the Cardiovascular Research Center Aalst (Belgium) and as of 2008 he was appointed as Director of the related Clinical Research Unit. In 2013, he has been visiting professor at the II Faculty of Medicine of the University of Rome La Sapienza. In 2013, he obtained the Italian scientific certification of Associate Professor of Cardiology. In 2014, he has been appointed as Associate Professor of Cardiology at the Department of Advanced Biomedical Sciences of the University of Naples Federico II. In 2017, he obtained the Italian scientific certification as Full Professor of Cardiology. In 2018, he is been appointed as Full Professor of Cardiology at the Department of Advanced Biomedical Sciences of the University of Naples Federico II.

Active areas of research

Prof. Barbato has been author of more than 240 peer-reviewed articles (see PubMed) in the field of pathophysiology of the coronary flow, of the ischemic cardiomyopathy, interventional cardiology, and platelet pathophysiology. He has been member of several Scientific and Learned Societies, and member of Editorial Boards of scientific journals (European Heart Journal, Journal Cardiovascular Translational Research, Journal Cardiovascular Medicine). He has served as member of the Programme Committee of the EuroPCR and of the EAPCI. As of 2014, he has chaired the National Cardiac Societies and International Affairs Committee of the EAPCI. As of 2018, he serves as EAPCI secretary. He has been recipient of National and International research awards (Scholar in Cardiology and William Harvey prize of the Italian Society of Cardiology, and Parmley prize of the American College of Cardiology).



[Martine Gilard](#)

Brest Hospital University, France

Professor Martine Gilard, MD, PhD, FESC is the Director of Interventional Cardiology department at Brest Hospital University. She is also responsible for the cardiac imaging department (MSCT and MRI). She specializes in endocoronary imaging and physiology. She performs all structural interventions except the left appendage closure within the department. She is past president of the French Society of Cardiology since end of January 2020 and has been involved in the EAPCI association since 2009.

Sigrun Halvorsen

Oslo University Hospital and University of Oslo, Norway

Curriculum Vitae

Professional qualifications:

2015: Women's Transforming Leadership course, University of Oxford/Saïd Business School, Oxford, UK
2004: Management Training program (Team Management), ECTS Credits 30
2000: Board Certification in Cardiology
1997: Board Certification in Internal Medicine
1995: Dr. med. (Ph.D.) in the field of Coagulation/Fibrinolysis.
1983: Cand. med. (M.D.) Faculty of Medicine, University of Oslo

Previous training and positions:

November 2014 - today: Professor of Cardiology, University of Oslo
Sept 2013 – today: Head of Cardiology, Oslo University Hospital Ullevål, Oslo.
2011-2013: Section Head and Associate Professor, Department of Cardiology, Oslo University Hospital Ullevål, Oslo.
2001-2010: Chief Physician, Department of Cardiology, Oslo University Hospital, Oslo
1994-2000: Residency in Internal Medicine and Cardiology, Ullevål University Hospital, Oslo
1989-94: Research and Teaching Fellow, Coagulation Laboratory, Ullevål Hospital, Oslo
1987-89: Residency in Internal Medicine, Ullevål University Hospital, Oslo

Publications: 160 peer-reviewed original publications in international journals.
H-index 38, 22134 citations.

Principal research interests: Anti-thrombotic treatment, Treatment of Acute Myocardial Infarction, Cardiac markers, Cardiovascular epidemiology

ESC activities: Fellow of the ESC (FESC) from 2008

Board member of ESC WG on Thrombosis for the period 2012-2016.

Board Member of the ESC Association of Acute CardioVascular Care (ESC-ACVA) 2016-2020. Chair of the Scientific Documents Group, ESC-ACVA, 2018-2020

Member of the ESC-Committee for Practice Guidelines 2018-2020

Member of the ESC-Congress Programme committee 2018-2020

Member of several ESC guideline Task Forces 2012-2020



[John William McEvoy](#)

NUI Galway, University Hospital, Ireland

J. William ("Bill") McEvoy is Professor of Preventive Cardiology at NUI Galway and a Consultant Cardiologist at University Hospital Galway, IRL. He also serves as Medical and Research Director of the Irish National Institute for Prevention and Cardiovascular Health (NIPC). Prof. McEvoy is 2004 first class honours graduate of UCC School of Medicine, Cork, IRL. He undertook senior house officer and cardiology registrar training at the Mater University Hospital in Dublin. In 2008, he joined the Osler Medical Housestaff at the Johns Hopkins Hospital and University School of Medicine in Baltimore, Maryland, USA. After internal medicine residency, he subsequently completed cardiology fellowship at Hopkins including advanced training in cardiac prevention, cardiac imaging, and cardiovascular epidemiology. He received the Johns Hopkins Department of Medicine teaching award for fellows in 2013. He was the inaugural Pollin Cardiovascular Prevention Fellow under Prof. Roger Blumenthal in 2013 and also served as the Hopkins Chief Cardiology Fellow in 2014 under Prof. Steven Schulman. He holds Masters degrees in cardiovascular epidemiology from the Johns Hopkins Bloomberg School of Public Health and in the education of health professionals from the Johns Hopkins School of Education. Prior to returning to Ireland in 2018, Prof. McEvoy was an Assistant Professor on the cardiology faculty at Johns Hopkins for 3 years, with clinical roles in the cardiac intensive care unit and in the Ciccarone primary and secondary cardiovascular prevention centre.

Prof. McEvoy's research focuses on preventive cardiology; with an emphasis on hypertension, risk assessment, and atherosclerosis. His research has resulted in numerous peer-reviewed publications, grants and awards. He was a member of the writing committee for the 2019 AHA/ACC primary CVD prevention guideline and wrote the aspirin section of this guideline.



[Martin van Eickels](#)

Bayer AG, Germany

Senior Vice President and Head of Medical Affairs Therapeutic Areas, Bayer AG. Dr van Eickels is responsible for the global medical and scientific strategy and activities for all Therapeutic Areas (at Bayer Pharmaceuticals). These include cardiovascular, thrombosis, hematology, women's health, pulmonology as well as established products.

Dr van Eickels has more than 20 years' experience in academic medicine and the pharmaceutical industry. He received his MD from the University of Bonn in 1995 and trained in Internal Medicine and Cardiology at the University of Bonn, Germany, University of Maastricht, the Netherlands and Tufts University, USA before joining the pharmaceutical industry as a cardiovascular pharmacologist for Aventis in 2003.

In 2005 Dr van Eickels joined the Global Clinical Development Department of Sanofi Aventis, where he was responsible for late stage development and registration of dronedarone, the first antiarrhythmic drug in more than 20 years that was registered and launched worldwide for the treatment of patients with atrial fibrillation.

In 2010 Dr van Eickels joined the Global Medical Affairs Department at Bayer HealthCare working in the Therapeutic Area Thrombosis, where led the efforts in translating the study results for Xarelto into clinical practice and played a pivotal role in setting up the unprecedented life cycle program for Xarelto, that upon completion will have included more than 275 000 patients in clinical and real life studies. During the following years Dr van Eickels expanded his responsibilities covering all cardiovascular products at Bayer.

Since 2018 Dr van Eickels leads all Therapeutic Areas in Global Medical Affairs for Bayer, developing a state of the art Global Medical Affairs group generating interpreting and communicating data to translate science into clinical practice to improve patients life's.



[Dr Nick West](#)

Abbott, USA

Dr Nick West is the Chief Medical Officer and Divisional President of Global Medical Affairs at Abbott Vascular. He originally graduated in medicine from Trinity Hall, University of Cambridge and St. Thomas' Hospital Medical School, London. He trained in interventional cardiology at the John Radcliffe Hospital, Oxford and Green Lane Hospital, Auckland, New Zealand. His postgraduate research in vascular biology, undertaken in the Department of Cardiovascular Medicine, University of Oxford and at Duke University, led to the award of the Sir Lionel Whitby Medal and the Sir Walter Langdon-Brown Prize at the University of Cambridge. Until recently he was an interventional cardiologist at the Royal Papworth Hospital, Cambridge, UK; he has published over 100 peer-reviewed papers & book chapters on topics including coronary physiology/microvascular function, intracoronary imaging/vulnerable plaque detection, acute myocardial infarction and use of bioresorbable scaffolds. He was also cofounder of the Cambridge-based biotechnology company, PlaqueTec Ltd.